A new class of drugs, known as JAK inhibitors, is showing significant promise in treating Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition that affects an estimated one in 100 people. These medications, already used for conditions like rheumatoid arthritis and eczema, work by targeting the underlying inflammation that drives HS.
HS causes painful, boil-like lumps to form deep under the skin, typically in areas such as the armpits and groin. The condition arises when hair follicles become blocked, and flare-ups can resemble ingrown hairs. Without effective treatment, HS can lead to weeping sores that may require surgical removal of affected skin.
Historically, treatment options have been limited to antibiotics, antibacterial washes, and pain relief. However, for many individuals with severe HS, these methods are insufficient to clear outbreaks or prevent recurrence. Experts suggest that JAK inhibitors could be a "gamechanger" for early or milder cases of HS, though they cannot reverse severe skin damage in advanced stages.
In the United States, JAK inhibitors and other biologic drugs are already being used to manage HS, with some studies indicating a significant reduction in inflammatory nodules and abscesses. One study published in Nature found that the JAK inhibitor povorcitinib reduced these symptoms by over 50 percent in HS patients.
While these advancements are offering new hope, access in the UK is currently hampered by pricing issues, according to Dr. Abirami Pararajasingam, a consultant dermatologist and spokesperson for the British Skin Foundation. She noted that the US is more proactive in prescribing these medications due to fewer restrictions.
Dr. Beibei Du-Harpur, a clinical lecturer in dermatology at King's College London, emphasized the importance of early diagnosis and treatment to prevent the worst damage from HS. She highlighted that HS can be difficult to diagnose, often taking up to ten years in the UK, leading many patients to live with the condition without understanding it. A lack of awareness among both the public and clinicians contributes to diagnostic delays.
The exact cause of HS remains unclear, but genetic factors are thought to play a role in about one-third of cases. Other contributing factors include being overweight or obese and smoking. Nicotine can lead to abnormal skin thickening that blocks hair follicles, while excess fat tissue releases chemicals that promote inflammation. However, some individuals are simply predisposed to HS due to their hair follicle and oil gland structure, regardless of lifestyle factors.
For many years, Laurelle-Maria Sterling, who has lived with HS since her teens, experienced frequent hospital visits and multiple courses of antibiotics that did not resolve her condition. Four years ago, she began treatment with adalimumab, a drug also used for rheumatoid arthritis and psoriasis. She reported that the medication calmed her inflammation, significantly reducing the severity of her flare-ups.
Experts anticipate that JAK inhibitor drugs will become more widely available to NHS patients for HS within the next one to two years. This increased accessibility could significantly improve the quality of life for thousands affected by this painful and often embarrassing condition.